Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pediatr Dermatol ; 40(6): 1064-1067, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37667982

RESUMEN

Aseptic facial granuloma is a rare pediatric disease, presenting with asymptomatic facial nodules on the cheeks or the eyelids and may represent a form of granulomatous rosacea in children. In this retrospective case series, 12 children with aseptic facial granuloma were treated with oral macrolides (erythromycin or roxithromycin) resulting in a healing of the lesions within a mean treatment time of 5.25 months with no recurrences. The treatment was mainly well tolerated. Oral macrolides may be effective in the treatment of patients with aseptic facial granuloma.


Asunto(s)
Dermatosis Facial , Rosácea , Niño , Humanos , Macrólidos/uso terapéutico , Estudios Retrospectivos , Antibacterianos/uso terapéutico , Granuloma/tratamiento farmacológico , Granuloma/patología , Rosácea/tratamiento farmacológico , Mejilla/patología , Dermatosis Facial/tratamiento farmacológico , Dermatosis Facial/patología
2.
Diagnostics (Basel) ; 14(15)2024 Jul 30.
Artículo en Inglés | MEDLINE | ID: mdl-39125519

RESUMEN

BACKGROUND: Next-generation sequencing (NGS) is the most commonly used method for determining BRAF mutational status in patients with advanced melanoma. Automated PCR-based methods, such as the IdyllaTM system, are increasingly used for mutation diagnostics, but it is unclear what impact the choice of diagnostic method has on the management of melanoma. OBJECTIVES: To compare the concordance rate of BRAF V600 mutational analysis using IdyllaTM and NGS and to analyze the technical and clinical turnaround time. The clinical relevance is compared by analyzing the impact on the treatment decision. METHODS: In this monocentric prospective cohort study, the BRAF mutation status of 51 patients was determined using both methods in parallel. RESULTS: BRAF V600 mutation was detected in 23/51 cases (45%). IdyllaTM showed a 100% concordant result with a faster turnaround time (0.2 days) compared to NGS (12.2 days). In general, less tumor material was required for IdyllaTM than for NGS. Most patients received immunotherapy as a first-line therapy regardless of the BRAF V600 status. CONCLUSIONS: IdyllaTM testing proved to be a reliable and rapid alternative to NGS in the determination of BRAF V600 mutation. Although BRAF. status was available earlier, this had no influence on the treatment decision in most cases.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA